In Brain News, Charity News, Press Releases, Research News

The magic of the ordinary . . .

We know from our daily interactions with you that after a brain tumour diagnosis the sentiments expressed more than anything else are the threat to way of life, lack of behaviour controls, impact on relationships, loss of identity, systemic problems leading to isolation. 


We know too that all things brain cancer have been the Cinderella of the oncology world, for many reasons, not just financial. For example, brain tumours are a complex disease with complex biology. The brain is delicate and privileged site that doesn’t respond well to interference. We have a small research community that has struggled to find anything transformative in the treatment of brain cancer. It’s an unlikely career choice for future medics; subspecialty training needs invigorating. And the small cohorts of patients mean that research is hard to do.

Tessa Jowell’s legacy

2018 has seen significant progress addressing these challenges, and it is important to note the influence that the late Dame Tessa Jowell has had on driving change and laying the foundations for a new brain tumour landscape in the UK.

Inspired and catalysed by the sad news of Tessa Jowell’s death from glioblastoma (and aggressive and as yet uncurable form of brain tumour) in May 2018, much is changing in the brain tumour research landscape. This is not about more of the same; we need to do things differently, be disruptive and challenging if we’re to reap the benefits of this one chance to get things right. We will ensure that the community’s voice is in the DNA of the TJBCM.

So it is with some excitement, intrepidation and relief that at last we have an opportunity to put this right. And this is down to the legacy of Tessa, and her amazing daughter Jess Mills. Jess has eloquently reflected on the experience she’s been through with her mum and explains the need ‘to re-establish the ‘magic of the ordinary’- to enable patients and families to live with a sense of peace and assurance that their most loved one are getting the best possible care.’

We now have committed Government funding invested through the NIHR, and with financial commitment from CRUK, and with the right focus and the right people on board, we should at last see traction in treating this horrible disease.

So what is the TJBCM?


The TJBCM serves as a national convening body, uniting professional, patient, charity and government groups to share information and work together to eradicate brain tumours. The mission puts patients first and foremost, and its aim is to selflessly share insights, knowledge and resources.

We are privileged to be integral to the TJBCM, which means that we can keep you, the patient and the carer, central. We are inspired by you. This is because you are very engaged with the challenges that we all face. You are powerful, vocal force that is happy to support what’s right and challenge what’s wrong with the brain tumour landscape, and as a movement, you are effective in solving the problems we face.

Proof of this can be found in the evolution of the charity landscape in recent years. A nation of people who have been touched by brain cancer has been mobilised to make the world better for people with a brain tumour in the future, and the brain tumour charities are the conduit for this change.

We want each of the 60,000 people who are living with a brain tumour in the UK, and their caregivers, to have parity of care which is second to none, so that there is never any doubt in anyone’s mind that what they are experiencing is the best it can be. We want everyone to know the magic of the ordinary.

You can read more about what the TJBCM means for the brain tumour community here:

nhs long term plantanya with book


The Brain Tumour Data Dashboard lets you explore up -to-date, population level data about the brain tumours diagnosed in England between 2013 and 2015. Using the drop down menus on the left you can select different groups of patients to view in the charts below. In these charts the number of patients for every 100 diagnoses is displayed as images of people. Patients have been grouped by date of diagnosis, type of tumour, age, gender, and region in England.

For each group of patients you can explore the different routes to diagnosis, the proportion of those who received chemotherapy or radiotherapy, as well as the survival of the patients within each group. For more information about what these metrics mean please see the glossary.

How to use

  1. Select the year of diagnosis using the drop down menu.
  2. Select your patient group of interest from the four drop down menus in the following order:
    1. Tumour group
    2. Age at diagnosis
    3. Region of England
    4. Gender of patient
  3. To view a second chart to compare different groups of patients, click the ‘compare’ button.The second chart will appear below the first chart.

*Note that the tool is best used on a laptop or tablet rather than a mobile phone*

Unavailable data

Some of the data in these charts is not available.There are two main reasons for this:

  1. How the data has been grouped

If you cannot select a patient group from the drop down menus, the data is unavailable because of how the data has been organised.

Public Health England has grouped the data like a branching tree. The bottom of the tree contains all the patients with brain tumours, and then each branch divides the data by a certain characteristics, like age, or location of tumour. But the data is divided in an order, starting with location of the tumour (endocrine or brain), then by age, region, and gender. Age is at the start because it makes a bigger difference to survival rates and treatment rates than gender or region. Sometimes, after the data has been split by type of tumour and age, there is not enough data to be split again. This is because to protect patient confidentiality groups cannot contain less than 100 patients. Because some groups cannot be split further, you cannot create ‘totals’ for everyone by region or gender. For example, you cannot see results for all ages by region, or all brain tumours by gender. If these totals were calculated and released, it might be possible to identify patients, which is why Public Health England cannot release this data.

  1. Statistical reasons and data availability

If you can select a patient group from the chart menus, but the chart does not display, the data is unavailable for one of several reasons:

  1. Data is not yet available for the selected year from Public Health England.
  2. Data is not available because the data quality is too poor to release this statistic.
  3. Data is not available as the statistic is not appropriate for this group.
  4. Data is not available because the standard error of the estimate was greater than 20% and so the estimate has been supressed.

Up to date brain tumour data

Brain tumour data may influence the decisions you make about your care. Data also helps you understand the bigger picture, or landscape, in which you find yourself.

Brain tumour data and statistics influence the focus, and work of organisations like brainstrust. The information helps us to understand the scale and impact of the problems we are setting out to solve.

This tool helps you understand the landscape in which you find yourself having been diagnosed with a brain tumour. This landscape can be particularly tricky to navigate as there are many different types of brain tumour, all of which have a different impact.

The information you see represents the most up-to-date, official, population level brain tumour data available for England. Over time we will be adding to the brain tumour data available and publishing reports, with recommendations, as a result of what we learn from this data.

The data behind this content has come from Public Health England’s National Cancer Registration and Analysis Service (NCRAS) and is a direct result of the ‘Get Data Out’ project.

This project provides anonymised population level brain tumour data for public use in the form of standard output tables, accessible here:


The number or rate (per head of population) of new cases of a disease diagnosed in a given population during a specified time period (usually a calendar year). The crude rate is the total number of cases divided by the mid-year population, usually expressed per 100,000 population.


Malignant tumours which grow by invasion into surrounding tissues and have the ability to metastasise to distant sites


The number or rate (per head of population) of deaths in a given population during a specified time period (usually a calendar year). The crude rate is the total number of deaths divided by the mid-year population, usually expressed per 100,000 population.


Not cancerousNon-malignant tumours may grow larger but do not spread to other parts of the body.


The length of time from the date of diagnosis for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the survival is one way to see how well a new treatment works. Also called ‘overall survival’ or ‘OS’.

Routes to Diagnosis

Under the ‘Routes to Diagnosis’ tab in the Brain Tumour Data Dashboard, you can explore the ways patients have been diagnosed with brain tumours. There are many ways, or routes, for cancers to be diagnosed in the NHS. A ‘route to diagnosis’ is the series of events between a patient and the healthcare system that leads to a diagnosis of cancer. The routes include:

  1. Two Week Wait

Patients are urgently referred by their GP for suspected cancer via the Two Week Wait system and are seen by a specialist within 2 weeks where they are diagnosed.

  1. GP referral

Diagnosis via a GP referral includes routine and urgent referrals where the patient was not referred under the Two Week Wait system.

  1. Emergency Presentation

Cancers can be diagnosed via emergency situations such as via A&E, emergency GP referral, emergency transfer or emergency admission.

  1. Outpatient

Outpatient cancer diagnoses include diagnoses via an elective route which started with an outpatient appointment that is either a self-referral or consultant to consultant referral. (It does not include those under the Two Week Wait referral system).

  1. Inpatient elective

Diagnosis via an inpatient elective route is where diagnosis occurs after the patient has been admitted into secondary care from a waiting list, or where the admission is booked or planned.

  1. Death Certificate Only

Diagnoses made by Death Certificate Only are made where there is no more information about the cancer diagnosis other than the cancer related death notifications. The date of diagnosis is the same as that of the date of death.

  1. Unknown

For some patients with a cancer diagnosis, there is no relevant data available to understand the route to diagnosis.


More information

If any of the statistical terms in this section of the brainstrust website are hard to understand, we recommend looking them up here:

Cancer Research UK’s Cancer Statistics Explained

If you are looking for help understanding terms relating specifically to brain tumours, and treatment, then the brainstrust glossary is available here: